Patent Classification

Treatment, Cancer/Tumor

1. Method for supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs and a device for supporting a diagnosis for an effect of a treatment by using anthracycline anticancer drugs
    
2. RNA from cytology samples to diagnose disease
    
3. Compositions for regulation of tumor necrosis factor-alpha
    
4. Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
    
5. Method for monitoring early treatment response
    
6. Human monoclonal antibodies to CD70
    
7. Tumor suppressor gene
    
8. Method and composition for hyperthermally treating cells
    
9. HDAC inhibitors and hormone targeted drugs for the treatment of cancer
    
10. Compositions and methods of use for therapeutic antibodies
     
11. Monoclonal antibodies to basic fibroblast growth factor
     
12. Tumor antigen protein SART-3 and tumor antigen peptides thereof
     
13. Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
     
14. Intralymphatic chemotherapy drug carriers
     
15. Cancer therapy sensitizer
     
16. Methods for detecting and monitoring cancer using extracellular RNA
     
17. Determining the capability of a test compound to affect solid tumor stem cells
     
18. Combination therapy for treating disease
     
19. Activation of Egr-1 promoter by DNA damaging chemotherapeutics
     
20. Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
     
21. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
     
22. Gene expression profiling of EGFR positive cancer
     
23. Hibiscusanthocyanins for inhibiting cancers
     
24. Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
     
25. Laser-activated nanothermolysis of cells
     
26. Stem cell factor for preventing chemotherapy-induced depletion of blood cells
     
27. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
     
28. Chemotherapy method using x-rays
     
29. Antibody molecules specific to human tumour necrosis factor alpha
     
30. Compositions and methods for targeting cancer-specific transcription complexes
     
31. Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
     
32. Annexin proteins and autoantibodies as serum markers for cancer
     
33. Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester
     
34. Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy
     
35. Neoplasm specific antibodies and uses thereof
     
36. Antibodies that bind specifically to human RON protein
     
37. Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
     
38. Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders
     
39. Antineoplastic agents targeted via glut transporters
     
40. Predicting response to chemotherapy using gene expression markers
     
41. Antibody against fibroblast growth factor-23
     
42. PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
     
43. TRAIL receptor-binding agents and uses of the same
     
44. Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies
     
45. Breast, gastric and prostate cancer associated antigens and uses therefor
     
46. Gene expression markers for predicting response to chemotherapy
     
47. Neoepitope detection of disease using protein arrays
     
48. Interfering RNAs against the promoter region of P53
     
49. Framework residue substituted humanized COL-1 antibodies and their use
     
50. Composition for treating cancer cells and synthetic method for the same
     
51. Saposin C-DOPS: a novel anti-tumor agent
     
52. Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers
     
53. MN gene and protein
     
54. Methods of using corticotropin-releasing factor for the use of the treatment of cancer
     
55. Increased T-cell tumor infiltration by mutant LIGHT
     
56. Antibody compositions for the diagnosis and treatment of tumor
     
57. Micromonospora species that produces a bafilomycin-like metabolite
     
58. Receptor coupling agents and compositions thereof
     
59. Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
     
60. Methods, systems, and associated implantable devices for detecting radiation in patients undergoing treatment for cancer
     
61. Methods for damaging cells using effector function of anti-DSC2 antibody
     
62. Methods for evaluating drug-resistance gene expression in the cancer patient
     
63. Small interference RNA gene therapy
     
64. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyl transferase
     
65. Microorganisms for therapy
     
66. Antibodies to tumor necrosis factor receptor associated factor polypeptides
     
67. Use of interleukin-18 inhibitors to inhibit tumor metastasis
     
68. Use of gene expression profiling to predict survival in cancer patient
     
69. Methods of treating and detecting cancer using viruses
     
70. Prediction of likelihood of cancer recurrence
     
71. Anti-EGFR antibodies
     
72. Mammalian tumor susceptibility gene products and their uses
     
73. Molecular characteristics of non-small cell lung cancer
     
74. Therapeutic use of anti-CS1 antibodies
     
75. TFIIS and GDOWN1 as targets for cancer therapy
     
76. Prevention of cisplatin induced deafness
     
77. Combined methods for tumor coagulation and tumor treatment
     
78. System and method for inhibiting cellular proliferation with tachykinins
     
79. Liposomes coated with selected antibodies that bind to aminophospholipids
     
80. Processes of making and using pharmaceutical formulations of antineoplastic agents
     
81. Cell growth inhibitor containing anti-PepT antibody
     
82. Methods and compositions for modulating drug activity through telomere damage
     
83. ErbB2 and ErbB3 chimeric heteromultimer adhesins
     
84. Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
     
85. Selective targeting of apoptotic cells
     
86. BAFF receptor polypeptides
     
87. Chemical induced intracellular hyperthermia
     
88. Co-administration of cG250 and IL-2 or IFN-.alpha. for treating cancer such as renal cell carcinomas
     
89. Radioimmunoconjugates for targeted alpha therapy
     
90. HER-2 binding antagonists
     
91. Antibodies against tumor surface antigens
     
92. Method for monitoring early treatment response
     
93. Ovr110 antibody compositions and methods of use
     
94. Method of increasing radiation sensitivity by inhibition of beta one integrin
     
95. Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen
     
96. Methods for inhibiting heregulin and treating cancer
     
97. Nanotubes for cancer therapy and diagnostics
     
98. Method for sorting tumor cells
     
99. Tumour necrosis factor binding ligands
     
100. Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
      
101. Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
      
102. Oncolytic virus therapy
      
103. Method for detecting multi-drug resistance
      
104. Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
      
105. Methods of treating various cancers using melanoma differentiation associated protein-7
      
106. Methods for assessing efficacy of chemotherapeutic agents
      
107. Antitumoral treatments
      
108. Combined cancer treatment methods using selected antibodies to aminophospholipids
      
109. Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
      
110. DNA vaccines against tumor growth and methods of use therof
      
111. Methods for identifying therapeutic agents and for treating disease
      
112. Cancer treatment with endothelin receptor antagonists
      
113. Methods and compositions for inducing autoimmunity in the treatment of cancers
      
114. LAGE-1 tumor associated nucleic acids
      
115. Composition and method of using carcinoma tumor cells
      
116. Tumor suppressor designated Hippo
      
117. Chimeric, human and humanized anti-CSAp monoclonal antibodies
      
118. Composition for treating cancer cells and preparation method for the same
      
119. Fusion proteins containing recombinant cytotoxic RNAses
      
120. Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
      
121. Immunogenic peptides for the treatment of prostate and breast cancer
      
122. Methods for enhancing antibody-induced cell lysis and treating cancer
      
123. Preventing bacterial or viral infectivity and composition containing infection preventing additive
      
124. Herbal composition for treating cancer
      
125. Tumour necrosis factor binding ligands
      
126. Expression profile algorithm and test for cancer prognosis
      
127. Method for producing cytotoxic T-cells
      
128. Immunotherapy for humans
      
129. Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
      
130. TWEAK receptor
      
131. Tumour necrosis factor binding ligands
      
132. Drug conjugate composition 
      
133. Compositions and methods for the diagnosis and treatment of tumor
      
134. Genetically modified tumor-targeted bacteria with reduced virulence
      
135. Method for distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma
      
136. System for characterization and mapping of tissue lesions
      
137. In-vivo energy depleting strategies for killing drug-resistant cancer cells
      
138. Cytotoxicity mediation of cells evidencing surface expression of CD44
      
139. Receptor modulated cancer protocols
      
140. Therapy-enhancing glucan
      
141. Methods of cancer diagnosis and therapy targeted against a cancer stem line
      
142. Drug conjugate composition
      
143. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
      
144. Photoimmunotherapies for cancer using combination therapies
      
145. Specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it
      
146. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
      
147. Antibody therapy of tumors
      
148. Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
      
149. Compositions and methods for identifying and targeting cancer cells of alimentary canal origin 
      
150. Type-1 ribosome-inactivating protein
      
151. Polyvalent conjugate vaccine for cancer
      
152. Use of taurolidine to treat tumors
      
153. Pro104 antibody compositions and methods of use
      
154. Cancer cell targeting gene delivery method
      
155. Modified cytokines for use in cancer therapy
      
156. Humanized anti-cmet antibodies
      
157. Reovirus for the treatment of neoplasia
      
158. Therapeutic agent for cachexia
      
159. Cytotoxicity mediation of cells evidencing surface expression of MCSP
      
160. Methods and compositions for determining risk of treatment toxicity
      
161. Methods and compositions for overcoming resistance to biologic and chemotherapy
      
162. Method of potentiating chemotherapy and treating solid tumors
      
163. Agent for treatment of cisplatin-resistant cancer
      
164. Compositions and methods for tumor-targeted delivery of effector molecules
      
165. Cancerous disease modifying antibodies
      
166. Enhanced immunization and suppression of oral tolerance
      
167. Chimeric tumor suppressor gene and protein
      
168. Fixed dosing of HER antibodies
      
169. Antibodies that recognize hyperproliferative cells and methods of making and using same
      
170. Genetically modified tumor-targeted bacteria with reduced virulence
      
171. Cancerous disease modifying antibodies
      
172. Methods to identify compounds useful for tumor sensitization to DNA damage
      
173. Method for treating cancer patients undergoing chemotherapy
      
174. Method of identifying compounds that induce cell death by necrosis
      
175. Compositions for allogeneic cell therapy
      
176. Anti-A33 antibody
      
177. Method of inhibiting insulin-like growth factor-1 (IGF-1) by IGF-1-antagonist peptides
      
178. Methods of cancer diagnosis and therapy targeted against a cancer stem line
      
179. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
      
180. Tumor antigen
      
181. Combined cancer treatment methods using antibodies to aminophospholipids
      
182. Compounds to promote regeneration of bone marrow
      
183. Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth
      
184. Enhancement of antibody-mediated immune responses
      
185. Non-squamous epithelium-specific transcription
      
186. Use of algae-derived physiologically active substances for treating a carcinomatous disease
      
187. hKIS composition and methods of use
      
188. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
      
189. Proteins with IL-6 inhibiting activity
      
190. Method for prognostic factor analysis regarding cancers
      
191. Cancerous disease modifying antibodies
      
192. Adenovirus serotype 30 (Ad30)
      
193. Determining a predisposition to cancer
      
194. Compositions and methods relating to prevention of chemotherapy-induced alopecia
      
195. Antibody molecules specific to human tumor necrosis factor alpha
      
196. Cancerous disease modifying antibodies
      
197. Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
      
198. Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
      
199. Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
      
200. Prostate-specific polypeptide pamp and encoding nucleic acid molecules
      
201. Method for limiting the growth of cancer cells using an attenuated measles virus
      
202. Compositions and methods for immunotherapy of cancer and infectious diseases
      
203. Endothelial cell expression patterns
      
204. Systemic gene delivery vehicles for the treatment of tumors
      
205. Ondansetron orally disintegrating tablets
      
206. Methods for preparing low molecular weight heparin with modified heparinase III
      
207. Method of using geranium oil and sophora root extracts as a supporting composition in cancer treatments
      
208. Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent
      
209. Water soluble paclitaxel prodrugs
      
210. Combined DNA vaccine and biological modifiers for cancer therapy
      
211. Composition for treatment or prevention of endometrial cancer and method of preventing or treating endometrial cancer using the composition
      
212. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
      
213. Humanized antibodies against CD3
      
214. Isolated proteins from a traditional Chinese medicine Yuzhu and use thereof
      
215. HER-2/neu fusion proteins
      
216. Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors
      
217. Compositions and methods for WT1 specific immunotherapy
      
218. Use of biomolecular targets in the treatment and visualization of tumors
      
219. Method of enhancing a targeted immune response against tumors
      
220. Loop peptide and TGF.alpha. for stimulating stem cell proliferation and migration
      
221. Methods of cancer therapy targeted against a cancer stem line
      
222. Sensitivity test to predict efficacy of anti-cancer therapies
      
223. Antibodies against human parathyroid hormone related protein
      
224. Securin is required for chromosomal stability in human cells
      
225. Genetically modified tumor-targeted bacteria with reduced virulence
      
226. Method of encapsulating metal complex within liposomes
      
227. Tumor-specific vector for gene therapy
      
228. Small particle liposome aerosols for delivery of anticancer drugs
      
229. Cancerous disease modifying antibodies
      
230. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
      
231. Vaccine against cancer diseases that are associated with the her-2/neu oncogene
      
232. Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent
      
233. Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
      
234. Small particle liposome aerosols for delivery of anti-cancer drugs
      
235. Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same
      
236. Methods for treating a patient undergoing chemotherapy
      
237. Prostate cancer specific internalizing human antibodies
      
238. Decreasing cell proliferation by decreasing levels of PP5
      
239. Q3 SPARC deletion mutant and uses thereof
      
240. Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
      
241. Bispecific single chain Fv antibody molecules and methods of use thereof
      
242. Compositions and method for WT1 specific immunotherapy
      
243. Combinatorial methods for inducing cancer cell death
      
244. Induction of immunity using inhibitors of granzymes
      
245. Immunotherapeutic methods using epitopes of WT-1 and GATA-1
      
246. Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
      
247. Methods for treating breast cancer using a mammary cell growth inhibitor
      
248. Modulators of the function of FAS/APO1 receptors
      
249. Antibodies against cancer
      
250. Molecular vaccine linking intercellular spreading protein to an antigen
      
251. Small peptides having anti-angiogenic and endothelial cell inhibition activity
      
252. Basal cell carcinoma tumor suppressor protein
      
253. Method of administering liposomal encapsulated taxane
      
254. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
      
255. Method for selecting therapeutic agents for cancer
      
256. Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions
      
257. Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
      
258. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
      
259. Cancer treatment composition and method using natural plant essential oils
      
260. Methods of treating various cancers using melanoma differentiation associated protein-7
      
261. Sphingomyelin enhancement of tumor therapy
      
262. Fully human antibodies against human 4-1BB
      
263. Method for monitoring early treatment response
      
264. Tumor radiosensitization using gene therapy
      
265. Herbal chemical composition for the treatment of cancer
      
266. Treatment of melanoma by reduction in clusterin levels
      
267. Hyperthermia agent for malignant tumor comprising cytokine and magnetic fine particles
      
268. Method of evaluating myelosuppressive state
      
269. Liposome-entrapped topoisomerase inhibitors
      
270. Nucleic acid mutation detection by analysis of saliva
      
271. Mutated Src oncogene composition and methods
      
272. Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapy
      
273. Methods and compositions for inhibition of metastasis
      
274. Methods for treating cancer using cytokine-expressing polynucleotides
      
275. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
      
276. CE7-specific chimeric T cell receptor
      
277. Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
      
278. Animal model of human hematopoietic tumor
      
279. Tumor therapy
      
280. Individualized anti-cancer antibodies
      
281. Modified vaccinia Ankara expressing p53 in cancer immunotherapy
      
282. Compounds and methods for modulating cell-adhesion mediated drug resistance
      
283. Anti-neovasculature preparations for cancer
      
284. Use of glutamate antagonists for the treatment of cancer
      
285. Classifying cancers
      
286. Calcium binding recombinant antibody against protein C
      
287. Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
      
288. Tumor vaccines
      
289. Liposome-entrapped topoisomerase inhibitors
      
290. Method for predicting tumor recurrence
      
291. Potentiation of anti-CD38-Immunotoxin cytotoxicity
      
292. Herpes virus strains for gene therapy
      
293. Monoclonal antibody cPAM4
      
294. Antibodies against tumor surface antigens
      
295. Method for detection of alterations in the DNA mismatch repair pathway
      
296. Human antibodies that bind human 17-A1/EpCAM tumor antigen
      
297. Use of novel agents inducing cell death in synergy with interferons
      
298. Methods for detecting DNA damage and screening for cancer therapeutics
      
299. Tumor suppressor designated TS10q23.3
      
300. Chemokines as adjuvants of immune response
      
301. Methods and compositions for diagnosing and suppressing metastasis thereof
      
302. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
      
303. Therapeutic anti-cytomegalovirus compounds
      
304. Detection and treatment of cancers of the lung
      
305. Myeloid precursor cell useful for gene therapy and for modulation of immune responses
      
306. ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
      
307. Protection of the female reproductive system from natural and artificial insults
      
308. Polypeptide encoded by a nucleic acid overexpressed in esophageal and lung tumor, and underexpressesd in kidney tumor and melanoma
      
309. Cancerous disease modifying antibodies
      
310. Method for identifying pre-neoplastic and/or neoplastic states in mammals
      
311. Use of RPL41 to treat infections and inhibit cancer
      
312. Anti-MUC-1 single chain antibodies for tumor targeting
      
313. Method for selective expression of therapeutic genes by hyperthermia
      
314. Physiologically active complex
      
315. Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
      
316. Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth
      
317. Imaging of drug accumulation as a guide to antitumor therapy
      
318. Anti-VEGF antibodies
      
319. Use of insulin-like growth factor binding protein 3 (IGF-BP3) for inhibition of tumor growth
      
320. Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
      
321. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
      
322. Reovirus for the treatment of ral-mediated cellular proliferative disorders
      
323. Treatment and diagnosis of cancer
      
324. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
      
325. Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
      
326. Rhob as a suppressor of cancer cell growth and cell transformation
      
327. Intra-tumoral administration of IL-12 encoding nucleic acid molecules
      
328. Imaging of drug accumulation as a guide to antitumor therapy
      
329. Method of determining a chemotherapeutic regimen based on glutathione-s transferase pi expression
      
330. Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
      
331. Methods and compositions for immunotherapy of cancer
      
332. Modified anti-EGFR antibodies with reduced immunogenicity
      
333. Specific human antibodies for selective cancer therapy
      
334. Liver tumor marker sequences
      
335. Method and product for treating cancer in pets
      
336. Targeted system for removing tumor cells from cell populations
      
337. Engineered superantigen for human therapy
      
338. Hyaluronic acid in the treatment of cancer
      
339. Method of cancer screening; method of cancer treatment; and method of diabetes treatment
      
340. Method and screening candidate compounds for drug against tumor
      
341. Testis-specific tubulin tyrosine-ligase-like protein, BGS42
      
342. Liposomal formulation of irinotecan
      
343. Technology of intracellular delivery of DNA oligonucleotides to improve drug activity
      
344. Enhancing cell-based immunotherapy
      
345. Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them
      
346. Nude mouse model for human neoplastic disease
      
347. Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
      
348. Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
      
349. Anti-TRAIL-R antibodies
      
350. Detection of ovarian cancer based upon alpha-haptoglobin levels
      
351. Method of determining cytokine dosage for myelosuppressive state
      
352. Treatment and diagnosis of prostate cancer
      
353. Cationic liposome delivery of taxanes to angiogenic blood vessels
      
354. Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells
      
355. Glypican-1 in human breast cancer
      
356. Gene cluster for production of the enediyne antitumor antibiotic C-1027
      
357. Multiple-delayed release anti-neoplastic product, use and formulation thereof
      
358. Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
      
359. Transgenic mouse expressing constitutively active hydrocarbon receptor
      
360. Method and compositions for treating hepatocellular cancer
      
361. Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors
      
362. Pharmaceutical composition for boron neutron capture therapy containing triphenylboroxin
      
363. Skeletal-targeted radiation to treat bone-associated pathologies
      
364. Methods and kits for diagnosing tumorigenicity
      
365. P450/acetaminophen genetically directed enzyme prodrug therapy (GDEPT)
      
366. Enhancing the circulating half-life of antibody-based fusion proteins
      
367. Toothpaste containing anticancer agents
      
368. Antibodies specifically reactive with a tumor necrosis factor related ligand
      
369. Methods of treatment by administering an anti-BCMA antibody
      
370. Gene expression profiling in biopsied tumor tissues
      
371. Anti-mesothelin antibodies having high binding affinity
      
372. Antioxidant enhancement of therapy for hyperproliferative conditions

 
373. Use of soluble costimulatory factor for tumor immuno-gene therapy
      
374. Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions
     
 
375. Liposomal camptothecins and uses thereof
      
376. Methods of treating and detecting cancer using viruses
      
377. Prediction of likelihood of cancer recurrence
      
378. Recombinant oncolytic adenovirus for human melanoma
      
379. X-ray guided drug delivery
      
380. Tumor necrosis factor receptor-5
      
381. Combination of bryostatin and paclitaxel for treating cancer
      
382. Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3
      
383. Surfactant prevention of vaginitis and lung complications from cancer chemotherapy
      
384. Cancer cell-inhibiting culture medium produced by culturing restricted entrapped cancer cells
      
385. Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for suppressing side-effect of radiotherapy and chemotherapy
      
386. Hematopoietic stem cell proliferating agents
      
387. Drosophila tumor necrosis factor class molecule polynucleotides and variants thereof
      
388. Recombinant adenoviruses for gene therapy in cancers
      
389. Sequences for targeting metastatic cells
      
390. Iodine uptake restoration in thyroid cancer
      
391. B7-DC, Dendritic cell co-stimulatory molecules
      
392. Liposomes
      
393. Neuroendocrine marker of prostate cancer and method for producing same
      
394. Fetally expressed gene as a human colon cancer marker
      
395. Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
      
396. Antibodies to the K12 protein
      
397. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
      
398. Method and apparatus for destroying dividing cells
      
399. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
      
400. Combinations of ceramide and chemotherapeutic agents for inducing tumor cell death
      
401. Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof
      
402. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
      
403. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
      
404. Cancerous disease modifying antibodies
      
405. Complex prescription of chinese medicine for the treatment of extensive cancer
      
406. Methods for identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity
      
407. Nucleic acid encoding an E1A gene product sensitizes HER-2/neu overexpressing cancer cells to chemotherapy
      
408. Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
      
409. Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
      
410. Pharmaceutical composition comprised of spider venoms, the production thereof, and its use for treating tumor diseases
      
411. Methods, compositions, and kits for organ protection during systemic anticancer therapy
      
412. Biological compositions and methods for treatment of testicular cancer
      
413. Gold-containing chemotherapeutic agents
      
414. Enhanced expression of transgenes
      
415. Biological compositions and methods for treatment of colorectal cancer
      
416. Biological compositions and methods for treatment of lung cancer
      
417. Anaerobe targeted enzyme-mediated prodrug therapy
      
418. Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
      
419. Delivery of a therapeutic agent in a formulation for reduced toxicity
      
420. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
      
421. Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
      
422. Attenuation of tumor growth, metastasis and angiogenesis
      
423. Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
      
424. Use of human prostrate cell lines in prostate cancer treatment
      
425. RRP sequences and knockout mice and uses thereof
      
426. Antibodies specific for CD44v6
      
427. Methods for detecting nucleic acids indicative of cancer
      
428. Process for producing humanized chimera antibody
      
429. Death domain proteins
      
430. Compositions and methods for tumor-targeted delivery of effector molecules
      
431. Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
      
432. Treatment of gastrointestinal stromal tumors
      
433. Recombinant bacterial cells for delivery of PNP to tumor cells
      
434. Methods of inhibiting immune response suppression by administering antibodies to OX-2
      
435. Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions
      
436. Method of modulating tumor immunity
      
437. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
      
438. Cell regulatory genes, encoded products, and uses related thereto
      
439. Antitumour vector constructs and methods
      
440. Epithelial cell growth inhibitors
      
441. Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
      
442. Method of reducing toxicity of anticancer agents
      
443. Composition having anticancer activity
      
444. Tumour-specific vector for gene therapy
      
445. Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
      
446. Method of cancer treatment
      
447. Human ovarian mesothelial cells and methods of isolation and uses thereof
      
448. Alginate capsules for use in the treatment of brain tumor
      
449. Non-invasive approach for assessing tumors in living animals
      
450. Treatment of metastatic disease
      
451. Recombinant mistletoe lectines
      
452. Method for reducing toxicity of combined chemotherapies
      
453. Melanoma therapy
      
454. Antibodies against the MUC18 antigen
      
455. Phosphopeptide-specific antibodies that are activity specific; methods of production and antibody uses
      
456. Selenium-containing pro-drugs for cancer therapy
      
457. Method and composition for treating prostate cancer
      
458. NF-κB activation inhibitors, and their pharmaceutical uses
      
459. Method of treating leukopenia with adenosine
      
460. Anti-neoplastic drug
      
461. Screening for drugs that affect TNF receptor releasing enzyme
      
462. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
      
463. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
      
464. Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
      
465. Conditioned media for inhibiting growth of tumor cells
      
466. Recombinant p53 adenovirus methods and compositions
      
467. Method for reducing toxicity of combined chemotherapies
      
468. Methods of treating hyperproliferative disorders using retinoblastoma fusion proteins
      
469. Methods for reducing the risk of breast cancer in and improving the health of women
      
470. Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
      
471. Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer
      
472. Mage-A12 antigenic peptides and uses thereof
      
473. Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
      
474. Medical compositions for intravesical treatment of bladder cancer
      
475. Use of parthenolide to inhibit cancer
      
476. Immunogenic cancer peptides and uses thereof
      
477. Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
      
478. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
      
479. Antitumoral composition based on immunogenic polypeptide with modified cell location
      
480. Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents
      
481. Treating cancer
      
482. Metalloproteinases
      
483. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
      
484. Methods for the early diagnosis of ovarian cancer
      
485. Therapeutic chemokine receptor antagonists
      
486. Recombinant anti-tumor RNAse
      
487. Genetically modified tumor-targeted bacteria with reduced virulence
      
488. Methods and compositions for destabilizing microtubules
      
489. Method of identifying and treating invasive carcinomas
      
490. Compositions and methods for the treatment and diagnosis of breast cancer
      
491. Immunogenic compositions against gastrin peptides
      
492. Methods of treating various cancers using melanoma differentiation associated protein
      
493. Predicting survival of patients with squamous cell carcinoma
      
494. Tumor targeted vector
      
495. Hybrid cells
      
496. Methods for activating natural killer (NK) cells and means for carrying out said methods
      
497. Combination drug therapy
      
498. Phytochemotherapy for cancer
      
499. Methods of detecting cancer based on prostasin
      
500. Colorectal neoplasia prophylaxis
      
501. Tie-2 ligand-3
      
502. Methods for using annexin for detecting cell death in vivo and treating associated conditions
      
503. Methods and modified cells for the treatment of cancer
      
504. Methods of diagnosing prostate cancer through the detection of the presence or absence of Pax 2 mRNA
      
505. Combination therapy using nucleic acids and radio therapy
      
506. Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
      
507. Aberrantly methylated genes as markers of breast malignancy
      
508. Diagnosis and treatment of malignant neoplasms
      
509. Verotoxin pharmaceutical compositions and medical treatments therewith
      
510. Use of NF-.kappa.B inhibition in combination therapy for cancer
      
511. Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy
      
512. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
      
513. Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
      
514. Variants of humanized anti carcinoma monoclonal antibody cc49
      
515. Cancer diagnostic method based upon DNA methylation differences
      
516. Agarose coated agarose beads containing cancer cells which produce cancer-cell proliferation-suppressing material
      
517. Mouse mammary tumor lines expressing estrogen and progesterone receptors
      
518. Methods for therapy of radiation cutaneous syndrome
      
519. Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
      
520. Methods for the administration of adenovirus p53
      
521. Cellular vaccines and immunotherapeutics and methods for their preparation
      
522. Immunotherapy using cytotoxic T lymphocytes (CTL)
      
523. Methods and compositions for inducing autoimmunity in the treatment of cancers
      
524. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
      
525. Compositions and methods for reducing radiation and drug resistance in cells
      
526. MPR-related ABC transporter encoding nucleic acids and methods of use thereof
      
527. Anti-tumor metallocomplexes of crude extracts from Canavalia ensiformis
      
528. Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
      
529. Diagnosis and treatment of malignant neoplasms
      
530. Cancerous disease modifying antibodies
      
531. Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
      
532. Methods for the early diagnosis of ovarian cancer
      
533. Tumor specific human monoclonal antibodies and methods of use
      
534. Diagnosis and treatment of malignant neoplasms
      
535. Cancer cell-inhibiting culture medium produced by culturing restricted entrapped cancer cells
      
536. Mammalian genes involved in viral infection and tumor suppression
      
537. Screen for risk for gastric adenocarcinoma
      
538. Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
      
539. Folypolyglutamyl synthetase gene transfer to enhance antifolate
      
540. Therapeutic uses of arglabin in combination with other chemotherapy agents
      
541. P53-specific T cell receptor for adoptive immunotherapy
      
542. Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
      
543. Reagents and methods for identifying and modulating expression of genes regulated by retinoids
      
544. Hydroxyapatite based drug delivery implant for cancer treatment
      
545. Herpes simplex virus expressing foreign genes and method for treating cancers therewith
      
546. Prevention of ovarian cancer by administration of products that induce transforming growth factor-.beta. and/or apoptosis in the ovarian epithelium
      
547. Methods for treating a patient undergoing chemotherapy
      
548. Method for detecting lymphoid tissue in tumor progression
      
549. Cancer gene therapy based on translational control of a suicide gene
      
550. Methods of inhibiting metastases
      
551. Interferon-beta use in the treatment of ewing's family of tumors
      
552. Compositions and methods for elimination of unwanted cells
      
553. Knockout mouse for the tumor suppressor gene ANX7
      
554. Methods of screening novel agents for use in cancer therapy and prevention
      
555. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
      
556. Use of adeno-associated viruses for decreasing the radiotherapy-induced or chemotherapy- induced resistance in cancer patients
      
557. Control of cancer growth through the interaction of [MET5]-enkephalin and the zeta receptor
      
558. Compositions and methods for the therapy and diagnosis of lung cancer (*Large Document, Long Loading Time)
      
559. Prevention of tumors with monoclonal antibodies against neu
      
560. Method of using fermented glycine max (L) extract for enhancing natural killer cell activity
      
561. Uses of transport proteins
      
562. Combination immunogene therapy
      
563. Stable human oral cancer cell carcinoma cell line
      
564. Water soluble paclitaxel derivatives
      
565. Method of imaging cell death in vivo
      
566. Synergistic compositions for the selective control of tumor tissue
      
567. Heat shock protein-based vaccines and immunotherapies
      
568. Methods to potentiate cancer therapies
      
569. Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
      
570. Method of preventing cancer recurrence
      
571. Vaccine adjuvants for immunotherapy of melanoma
      
572. Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
      
573. Glycosyltransferase vectors for treating cancer
      
574. Compounds and methods for therapy and diagnosis of lung cancer
      
575. Method of producing infectious reovirus
      
576. Treatment of breast cancer
      
577. Dominant negative deletion mutants of C-jun and their use in the prevention and treatment of cancer
      
578. Method for screening the risk of gastric cancer
      
579. Vasopermeability-enhancing conjugates
      
580. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
      
581. Process for preparation of a biomarker specific for O-acetylated sialic acid useful for diagnosing, monitoring treatment outcome, and predicting relapse of lymphoblastic leukemia
      
582. X-ray imaging of tumors with dextran carrier of platinum compounds
      
583. Vectors for the diagnosis and treatment of solid tumors including melanoma
      
584. Recognition of tumor-specific gene products in cancer
      
585. Methods for diagnosing and evaluating cancer
      
586. Mini-E1A gene and gene products
      
587. Methods and compositions for inhibiting the proliferation of prostate cancer cells
      
588. Method for enhancing the effectiveness of cancer therapies
      
589. Type-1 ribosome-inactivating protein
      
590. Human polyhomeotic 2 (hph2) acts as a tumor suppressor
      
591. Method for the prevention of colonic adenomas
      
592. Use of Mullerian inhibiting substance for treating excess androgen states
      
593. Cell-free assay using oncogene-induced apoptosis to identify inhibitors of apoptosis in drug-resistant cells
      
594. Compositions and methods for therapy of ovarian cancer
      
595. Human endogenous retrovirus in breast cancer
      
596. Pancreatic cancer genes
      
597. Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
      
598. Antitumor agent
      
599. Herpes simplex virus for treating unwanted hyperproliferative cell growth
      
600. Method for predicting tumor recurrence
      
601. Combination of selenium-containing compounds with cytostatics
      
602. Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
      
603. Methods and compositions for inhibiting the proliferation of prostate cancer cells
      
604. Selenium-containing pro-drugs for cancer therapy
      
605. Human cancer cell line malignantly altered by expression of angiogenic factor
      
606. Method for detecting and killing epithelial cancer cells
      
607. Herbal chemical composition for the treatment of cancer
      
608. Annexin proteins and autoantibodies as serum markers for cancer
      
609. Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
      
610. Method of blocking blood vessel growth using tie-2 ligand 2
      
611. Peptide with radio protective effect
      
612. Treatment of cancer with thymidine in combination with temozolamide
      
613. Herpes virus vectors for dendritic cells
      
614. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
      
615. Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
      
616. Monoclonal antibody against human telomerase catalytic subunit
      
617. Method for chemoprevention of prostate cancer
      
618. Method for the production of in vivo model of hepatocellular carcinoma without lung metastasis
      
619. Gel delivery vehicles for anticellular proliferative agents
      
620. Prognostic evaluation of cancer
      
621. Reparatives for chemosurgery and laser (thermal) therapy
      
622. Single chain antibody against mutant p53
      
623. Inducing cell apoptosis and treating cancer using 1-O-acetylbritannilactone or 1,6-O,O-diacetylbritannilactone
      
624. Compositions and methods for improved detection and classification of neoplasms
      
625. Methods and means for inducing apoptosis by interference in RNA processing
      
626. Method for inhibiting brain tumor or colon carcinoma
      
627. Antineoplastic combinations comprising
      
628. Active oxygen scavenger and cancer chemopreventer from Grifola
      
629. Identification of differentially methylated and mutated nucleic acids
      
630. Elevation of circulating blood histamine levels
      
631. Compounds for immunotherapy of prostate cancer and methods for their use
      
632. Screening assays for compounds that cause apoptosis and related compounds
      
633. Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
      
634. Methods for inducing the differentiation of monocytes into functional dendritic cells
      
635. TCF responsive element
      
636. Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
      
637. Lyophilizate of lipid complex of water insoluble porphyrins
      
638. Renal cell carcinoma treatment
      
639. HLA class I A2 tumor associated antigen peptides and vaccine compositions
      
640. Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
      
641. Microspheres for use in the treatment of cancer
      
642. Methods of detecting T-cell activation
      
643. Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
      
644. Synthesis, characterization, and application of pyridylazo bioconjugates as diagnostic and therapeutic agent
      
645. Bismuth-213 generator and uses thereof
      
646. Molecular chemotherapy enhancement of radiotherapy
      
647. Methods and compositions for modulating cell proliferation and cell death
      
648. Method for treating cancer having greater efficacy and reduced adverse effects
      
649. Immunotherapeutic agent for cancer containing nucleoidal component of bacterium as active ingredient
      
650. Recombinant yellow fever virus and method of use thereof
      
651. Method of treating cancer using tetraethyl thiuram disulfide
      
652. Compositions for the treatment and diagnosis of breast cancer and methods for their use
      
653. Mutants of the Rb and p53 genes and uses thereof
      
654. Compositions and methods for the treatment and diagnosis of breast cancer
      
655. IL-18/IGIF chemotherapeutic compositions
      
656. Human PEA3 is a tumor suppressor for cancer cells
      
657. Lymphoma-susceptible transgenic mice and methods for studying drug sensitivity of lymphomas
      
658. Pharmaceutical compositions comprising erythropoietin for treatment of cancer
      
659. Assay of YKL-40 as a marker for cancer
      
660. Therapeutic anti-cytomegalovirus compounds
      
661. Use of a context-dependent functional entity to enhance the efficacy of an agent
      
662. Use of substance P antagonists in the treatment of the adenocarcinomas
      
663. Tumoricidal T lymphocytes
      
664. FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
      
665. DFMO and celecoxib in combination for cancer chemoprevention and therapy
      
666. Parenteral Cisplatin emulsion
      
667. Ion exchange tumor targeting (IETT)
      
668. Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cell
      
669. Method for gene transfer to the central nervous system
      
670. Chemokine-tumor antigen fusion proteins as cancer vaccines
      
671. Methods for detection and treatment of neural cancers
      
672. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
      
673. Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
      
674. Nano-emulsion of 5-aminolevulinic acid
      
675. Tumor radiosensitization using gene therapy
      
676. Bi-and trispecific antibodies for the induction of anti-tumor immunity
      
677. Vaccine compositions for human papillomavirus
      
678. Molecular chemotherapy enhancement of radiotherapy
      
679. Compositions and methods for their preparation from lepidium
      
680. Lyophilizate of lipid complex of water insoluble camptothecins
      
681. Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
      
682. Method of treating cancer with anti-neurotrophin agents
      
683. Antigen carbohydrate compounds and their use in immunotherapy
      
684. Methods relating to modulation of cartilage cell growth and/or differentiation by modulation of NFATp activity
      
685. Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
      
686. Method of sensitizing tumor cells with adenovirus E1A
      
687. Anti-bax inhibitor protein antibodies
      
688. Human selenoprotein
      
689. Method for reducing radiation toxicity
      
690. Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
      
691. Sphingomyelin enhancement of tumor therapy
      
692. Methods and compositions for treating lipoxygenase-mediated disease states
      
693. Implantation of HSV-TK retrovirus producer cells to destroy glioma
      
694. Vaccina virus comprising cytokine and/or tumor associated antigen genes
      
695. Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers
      
696. Polyspecific binding molecules and uses thereof
      
697. Crystalline farnesyl protein transferase compositions and methods for use
      
698. Antibodies that specifically react with seroreactive regions on HPV 16 proteins E1 and E2
      
699. Adenoviral vectors encoding a cytokine and a conditionally lethal gene
      
700. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
      
701. Method of suppressing tumor cell growth by administering a decorin gene or gene product
      
702. Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
      
703. Vasopermeability-enhancing conjugates
      
704. DNA damaging agents in combination with tyrosine kinase inhibitors
      
705. Antibodies directed against trail
      
706. Anti-neoplastic compositions and uses thereof
      
707. Compounds and methods for therapy and diagnosis of lung cancer
      
708. Pharmaceutical composition and method for the treatment of neoplastic cells
      
709. cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine
      
710. Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
      
711. Injectable pharmaceutical composition comprising coated particles of camptothecin
      
712. Method of inducing resistance to tumor growth
      
713. Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
      
714. Compositions and methods for identifying antigens which elicit an immune response
      
715. Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
      
716. Synergistic tumorcidal response induced by histamine
      
717. Zinc ionophores as therapeutic agents
      
718. Method for inhibition of photocarcinogenesis or photoimmunosuppression using niacin
      
719. 35 kD tumor associated protein antigen: uses and methods of detection
      
720. Methods of using electron active compounds for managing cancer
      
721. Cell-cycle regulatory proteins, and uses related thereto
      
722. Monoclonal antibody to a human MDR1 multidrug resistance gene product and uses
      
723. Genetically modified tumor-targeted bacteria with reduce virulence
      
724. Uses for DNA structure-specific recognition protein
      
725. Multifunctional nanodevice platform
      

726. DNA vaccine and methods for its use
      

727. Stimulation of an immune response with antibodies labeled with the .alpha.-galactosyl epitope
      
728. Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
      
729. Use of garlic extract as both preventive and therapeutic agents for human prostate and bladder cancers
      
730. Method for inhibiting tumor invasion or spreading in a subject
      
731. Hydrophilic somatostatin analogs
      
732. Method of reducing side effects of chemotherapy in cancer patients
      
733. Production of chimeric antibodies with specificity to human tumor antigens
      
734. Human heparanase polypeptide and cDNA
      
735. Composition comprising tumor cells and extracts and method of using thereof
      
736. Pituitary-tumor-transforming-genes, and related products
      
737. VEGF-gelonin for targeting the vasculature of solid tumors
      
738. Methods for treating breast cancer using Mammastatin
      
739. Composition and method for contraception and treatment of tumors of the mammary glands
      
740. Genetically modified tumor-targeted bacteria with reduced virulence
      
741. Treatment of cancer using lipoic acid in combination with ascorbic acid
      
742. Immunotherapy of tumor with monoclonal antibody against the 17-1A antigen
      
743. Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer
      
744. Prevention of primary and metastatic neoplastic diseases with GP96-peptide complexes
      
745. Human chimeric antibody specific for the ganglioside GD3
      
746. Methods of treating diseased cells
      
747. RNA cancer vaccine and methods for its use
      
748. Monoclonal antibody which recognizes the oligosaccharide N-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
      
749. Assays for identifying functional alterations in the p53 tumor suppressor
      
750. Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemotherapy and radiotherapy
      
751. Method of enhancing the efficacy of anti-tumor agents
      
752. Methods for selectively occluding blood supplies to neoplasias
      
753. Human-derived bradeion proteins, DNA coding for the proteins, and uses thereof
      
754. Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins
      
755. Method of enhancing the effectiveness of DCK phosphorylated molecules
      
756. Formulation and method for treating neoplasms by inhalation
      
757. Method for the augmentation of gene expression
      
758. Method for inducing tumor immunity
      
759. Highly purified cytokine activating factor and methods of use
      
760. Anaerobe targeted enzyme-mediated prodrug therapy
      
761. Method and kit for epithelial cancer screening
      
762. Method of screening for a modulator of angiogenesis
      
763. Methods for preparation of vaccines against cancer
     
     
764. Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
     
     
765. Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
     
     
766. Hapten-conjugated mammalian cells and methods of making and using thereof
     
     
767. Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
     
     
768. Uteroglobin gene therapy for epithelial cell cancer
     
     
769. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
     
     
770. Method for the prevention and treatment of cachexia and anorexia
     
     
771. Prevention of infectious diseases with hsp90-peptide complexes
     
     
772. Use of herpes vectors for tumor therapy
     
     
773. Retinoblastoma fusion proteins
     
     
774. Cancer treatment
     
     
775. Method for treating cancer with a neurotoxin to improve patient function
     
     
776. Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide
     
     
777. Cellular immunogens comprising cognate proto-oxogenes
     
     
778. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
     
     
779. Nude mouse model for the growth and treatment of human neurally-derived tumors
     
     
780. Humanized antibodies that bind to the antigen bound by antibody NR-LU-13
     
     
781. Use of a melanoma differentiation associated gene (mda-7) for inducing apoptosis of a tumor cell
     
     
782. Peptide tumor cell growth inhibitors
     
     
783. Method for stimulating CTLs with peptides
     
     
784. Treatment of hyperproliferative disorders
     
     
785. Method of treating cancer with a tumor cell line having modified cytokine expression
     
     
786. Tumor specific internalizing antigens and methods for targeting therapeutic agents
     
     
787. High affinity humanized anti-TAG-72 monoclonalantibodies
     
     
788. Composition for treating cancer via liposomal aerosol formulation containing taxol
     
     
789. Therapeutic antiangiogenic endostatin compositions
     
     
790. Mimicking peptides in cancer therapy
     
     
791. Method for detection and treatment of breast cancer 
     
     
792. Locally injectable chemotherapeutics 
     
     
793. Therapy of cancer by insect cells containing recombinant baculovirus encoding genes 
     
     
794. Radiation enhanced gene therapy for tumors expressing a gene for a viral pyrimidine kinase in the presence of a 5'-halogenated pyrimidine 
     
     
795. Anti-cancer vaccine
      
     
796. Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
      
     
797. Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
      
     
798. Medicament for suppressing cancer metastasis
      
     
799. Method of using haptenized ovarian carcinoma tumor cells
      
     
800. Use of docetaxel for treating cancers
      
     
801. P202 is a tumor suppressor
      
     
802. Immune response enhancer 
      
803. Use of mCRP to slow cell growth and to promote maturation of cells
      
     
804. Method for treatment in gene therapy and use of guanine derivative therefor
      
     
805. Transferrin compositions to alleviate the side effects of cytotoxic drugs
      
     
806. Composition and method for the treatment of bladder cancer
      
     
807. Method for the prevention and treatment of cachexia and anorexia
      
     
808. Suppression of neu overexpression using a mini-E1A gene
      
     
809. Tumor cells with increased immunogenicity and uses therefors
      
     
810. Method of treating a tumor
      
811. Method of inducing resistance to tumor growth
      
     
812. Method of inducing apoptosis in cancer cells using an extract of Melothria indica Lou
      
     
813. Ultrasound enhanced chemotherapy
      
     
814. Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition
      
     
815. Recombinant human anti-Lewis Y antibodies
      
     
816. Pharmacokinetic modulating chemotherapy
      
     
817. Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
      
818. Methods and compositions for inducing autoimmunity in the treatment of cancers
      
     
819. Selective killing and diagnosis of p53+ neoplastic cells
      
     
820. Alteration of the cell cycle in vivo, and particularly for inducing apoptosis of tumor cells
      
     
821. Treating cancers associated with overexpression of class I family of receptor tyrosine kinases
      
     
822. Method of treating cancer with a 43 kD human cancer antigen
      
     
823. Isolation and structural elucidation of the human cancer cell growth inhibitory compound denominated agelagalastatin
      
     
824. Engineered cytotoxic ribonclease
      
     
825. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
      
     
826. Anti-TNF antibodies and peptides of human tumor necrosis factor
      
     
827. Interferon-gamma (IFN-.gamma.) inducing factor (IGIF, IL-18) and peptide fragment thereof
      
     
828. Self-assembled taxo-diterpenoid nanostructures
      
     
829. Enhanced expression of transgenes
      
     
830. Polynucleotides for inhibiting metastasis and tumor cell growth
      
     
831. Extract of Lepidium meyenii roots for pharmaceutical applications
      
     
832. Water soluble paclitaxel prodrugs
      
     
833. Prodrugs activated by targeted catalytic proteins
      
     
834. Use of inhaled retinoids in the prevention of cancer
      
     
835. Compositions and methods for tolerization in immune complex-mediated disease progression
      
     
836. Method for treating brain cancer with a conditionally lethal gene
      
     
837. Interleukin-12 inducer and medical composition
      
     
838. Vectors for DNA immunization against cervical cancer
      
     
839. Method for treating a patient with neoplasia by treatment with a platinum coordination complex
      
     
840. Cancer therapy using an oncogene product and a foreign MHC molecule
      
     
841. Multiple drug resistance gene atrD of Aspergillus nidulans
      
     
842. Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients
      
     
843. Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
      
     
844. Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
      
     
845. Gene therapy for solid tumors, papillomas and warts
      
     
846. Adjuvant incorporation into antigen carrying cells: compositions and methods
      
     
847. Pharmacological composition for treating cancer cells
      
848. Method to reduce the physiologic effects of drugs on mammals
      
     
849. Taxane derivatives for targeted therapy of cancer
      
     
850. Methods for treating a fibrin encapsulated tumor using a fibrin specific monoclonal antibody and compositions used therein
      
     
851. Cancer chemoprotective food products
      
     
852. Methods for preventing multidrug resistance in cancer cells
      
     
853. Heat shock protein 70 preparations in vaccination against cancer and infectious disease
      
     
854. Method for anticancer therapy using an herbal extract composition
      
     
855. Use of locally applied DNA fragments
      
     
856. Targeted system for removing tumor cells from cell populations